Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Pancreatic Neoplasms 13Neoplasm Metastasis 10Neoplasms 8Lung Neoplasms 6Colorectal Neoplasms 6Breast Neoplasms 6Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Melanoma 4Squamous Cell Carcinoma of Head and Neck 3Endometrial Neoplasms 3Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic cancer, adult 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1Pancreatic Cancer Non-resectable 1Pancreas Adenocarcinoma 1

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Inoperable Locally Advanced HER2-Negative Breast Cancer × Taxes × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡